Abstract: Thrombotic risk is associated with the estrogen dose and type of progestin in combined oral contraceptives. Studies published since 1990 showed that third-generation progestins have larger risk to contribute to thrombosis development than the second-generation. However, there are conflicts in the literature regarding the thrombotic risk associated to the drospirenone progestin. So, this study aimed to evaluate the effects of 3 formulations of contraceptives containing ethinylestradiol (EE) (20 and 30 mg) combined with drospirenone versus levonorgestrel combined with EE (30 mg) in hemostatic parameters.
INTRODUCTION
O ver 100 million women around the world use hormonal contraceptive methods. Among them, 93 million use combined oral contraceptives (COCs). 1 COCs are well tolerated by most women and present high contraceptive efficacy when used properly. 2 Hormonal contraceptives cause several metabolic effects on lipids, carbohydrates, and hemostatic parameters. 3 These changes may lead to the formation of an obstructive clot in face of an inadequate balance among procoagulant, anticoagulant, and fibrinolytic factors. 4 The association between the use of COCs and the incidence of venous thrombosis is well defined and has been confirmed in several observational studies. [5] [6] [7] [8] [9] [10] A study that compared the incidence of venous thrombosis in non-users and users of oral contraceptives younger than 30 years found that the relative risk of thrombosis for women younger than 30 years who use COCs is 3.1. 10, 11 Initially, the estrogen contained in contraceptives was considered the only responsible for the prothrombotic effects of hormonal contraception. In fact, a progressive reduction in the dose of estrogen reduced these side effects. 12 However, due to the increase in the incidence of thrombosis induced by contraceptives containing the same dose of estrogen and different progestagen, it was possible to observe that the hypercoagulant effect of the contraceptive is not strictly dependent on the dose of estrogen, but on the ''total estrogenicity'' of the estroprogestive formulation. The estrogenicity increases as the dose of estrogen increases, but decreases with the increase of the antiestrogenic activity of the progestagen. 13 Studies published since 1990 showed that third-generation progestins have a lower antiestrogenic activity in relation to the second-generation ones (levonorgestrel), and therefore, they are less potent to counterbalance the prothrombotic effects caused by the estrogen Table 1. 7,10, [14] [15] [16] There are conflicts in the literature regarding the thrombotic risk associated to the drospirenone progestin. Some studies reported an increase in the risk of thrombosis in face of the use of drospirenone, 9, 17, 18 whereas others have not found significant results. 19, 20 Drospirenone is an analogue of the antagonist of aldosterone, the spirolactone, which has antimineralocorticoid and antiandrogenic activity, besides being quite similar to the endogenous progesterone. 21 In face of the facts presented, this study aimed at evaluating the incidence of hemostatic changes in the Brazilian female population using contraceptives containing different doses of estrogen and types of progestins (drospirenone and levonorgestrel).
MATERIALS AND METHODS

Subjects and Study Protocol
Cross-sectional study with 70 women was distributed into The present study is part of a research protocol designed to evaluate the effect of 3 formulations of Hormonal Contraceptives in the expression of soluble adhesion molecules. 22 Sample size calculations were performed by using Proc Power in SAS 9.1 (SAS Institute, Cary, NC, USA). Considering comparisons between population means of the Soluble Intercellular Adhesion Molecule 1 by a 1-way analysis of variance (ANOVA), it was found that a sample size of 20 individuals at each group is sufficient for detecting a minimum difference of 40 ng/mL in soluble adhesion molecules between 2 of 4 groups at a significance level of 0.05, power of 0.80, and a standard deviation of 40 ng/mL.
Considering the limited number of participants (Figure 1 ), we assume that this is an underpowered study and all the results obtained in this study are considered as preliminary. The inclusion criteria adopted were: age between 18 and 30 years, body mass index (BMI) 19 to 30 kg/m 2 , user or non-user (control group) of contraceptives for a minimum period of 6 months and a maximum period of 24 months. Smokers, under the prescription of anti-inflammatory drugs and with a personal history of cardiovascular disease, hypertension, thromboembolism, chronic or acute hepatopathy, diabetes, or autoimmune disease, were excluded from the study. To obtain information such as frequency in the practice of physical exercise and family history of thrombosis, the volunteers answered a questionnaire.
The blood sample was collected in standardized conditions, between 08:00 and 10:00 AM, after at least 12 h of fasting. Sodium citrate (0.11 mol/L) was used as anticoagulant and the samples were centrifuged for 20 minutes at 2500g and stored at À708C, and after 6 months, the laboratorial parameters were analyzed in the plasma of the volunteers. The blood samples of all the groups were collected during the luteal phase of the menstrual cycle (21-28 days).
Measurements of Haemostatic Variables
The effect of the 3 formulations of contraceptives in the procoagulant parameters was analyzed through the determination of the activated partial thromboplastin time (aPTT), prothrombin time (PT), fibrinogen plasma concentration (Clauss method), and activity of the factors XII and VII in the plasma of the patients, with the use of an automatic coagulation analyzer (STart DIAGNOSTICA STAGO, Paris -France) according to the criteria of the manufacturer (Trinity Biotech-Ireland).
The determination of the variable marking coagulation F1 þ 2 (prothrombin fragment 1 þ 2) in the plasma was 
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established through immunoenzyme technique (Kit Enzygnost1, Siemens Germany). The anticoagulant variables analyzed were the activity of the antithrombin and the plasmatic concentration of Protein C and S. In these analyses, a chromogenic method was used to determine the activity of the antithrombin (Kit Berichrom Antithrombin III) with the assistance of the equipment BCS1XP. The concentration Protein C and S was determined by ELISA (Helena Laboratories, Beaumont, Texas).
The quantification of the fibrinolytic variable D-dimer was performed through automatized immunoenzyme technique with the use of the equipment and reagent VIDAS1D-Dimer Exclusion (BioMériuex, France). The activity of the antifibrinolytic variable PAI-1 was determined through chromogenic method (Berichrom PAI-1, Siemens, Germany) in the equipment BCS1XP.
All samples were processed concomitantly in the end of the study to minimize the interference of inter-assay variations.
Statistical Analysis
The population means of the variables, age and BMI, in the 4 groups of volunteers were compared using an ANOVA. Previously, Levene test was used to compare equality of variances. When significant differences were detected between the variances, Welch ANOVA was used to compare the population means. Otherwise, the traditional ANOVA was used. Fisher exact test was used to compare the frequencies of the practice of physical exercise and family history of thrombosis between the 4 groups.
An analysis of covariance was used to compare population means of the variables associated to the procoagulants, anticoagulants, fibrinolytics, and antifibrinolytics variables between the 4 groups of volunteers, considering adjustments for possible confounding effects of the covariates age, BMI, practice of physical exercise, and family history of thrombosis.
RESULTS
The authors recruited 72 women for this study. Among these, 70 were distributed into 4 groups (Figure 1) . During the period of study, 2 patients were excluded, as they presented incompatible values of BMI in relation to the values established as inclusion criteria.
The characteristics, age, BMI, frequency in the practice of physical exercise, and family history of thrombosis of the 4 groups, of women who participated in the study are presented in Table 1 .
In Table 2 , there is evidence that the age of the volunteers has approximate averages between populations of interest (P ¼ 0.07), but different variances (P < 0.01). There is a greater dispersion of age in Group IV, which consisted of the youngest and oldest women of this study.
The results obtained in the analysis of the coagulant, anticoagulant, and fibrinolytic variables of the women in the 4 groups of this study are presented in Table 3 .
The PT, in seconds, was significantly longer for patients in the control group in comparison with the patients who used the 3 formulations of contraceptives (DRSP/30EE, DRSP/20EE, and LNG/30EE). The contraceptive containing second-generation progestagen (LNG/30EE) presented a PT closer to that found in the control group. In the determination of the aPTT, there was a significant decrease in the value of this parameter for the group DRSP/20EE in comparison with the control group. In the quantification of the fibrinogen plasma concentration, the group DRSP/ 20EE presented a significantly increased value in relation to the control group. In the analysis of the activity percentage of the coagulation factors (FVII and FXII) and plasma concentration of F1 þ 2, no significant differences were found.
Regarding the anticoagulant parameters, the level of Protein C found in the plasma of the users of LNG/30EE was lower than in the others 3 groups. A significant decrease in the level of Protein S for the users of DRSP/30EE and DRSP/ 20EE was observed. No significant differences were found for the quantification of the activity percentage of the antithrombin in the plasma of the patients in the 4 evaluated groups.
As for the fibrinolysis analysis, a significant increase was found in the fibrinolytic parameter D-dimer for the group DRSP/20EE in comparison with the control group. Still in the fibrinolysis evaluation, a significant decrease was found in the anti-fibrinolytic parameter PA1-1 for the group DRSP/ 30EE in comparison with the other 3 studied groups (Control, DRSP/20EE, LNG/30EE).
DISCUSSION
In this study, the changes caused in the hemostasis were more expressive for the users of DRSP/20EE, in which it is possible to notice significant changes in 3 coagulant parameters (PT, aPTT, and fibrinogen), in the anticoagulant parameter Protein S, and in the fibrinolytic parameter (D-dimer), all favoring a state of hypercoagulation. The contraceptives containing DRSP/30EE and LNG/30EE promoted changes that favor hypercoagulability in the coagulant parameter PT and in the anticoagulant parameter Protein S and Protein C, respectively. These statistically significant findings were not followed by clinical significance. The results found in this study agree with Kluft et al, 23 who reported a decrease in the values of PT and aPTT in the 3 groups evaluated in their study (DRSP/30EE, DRSP/20EE, DSG/30EE). Although this same author already reported in the year 2000 that global tests such as PT and aPTT present inconclusive results about the clinical relevance of a drug, since different factors such as differences of handling of samples, use of tetracycline and antihistamines drugs, and lipemic samples may influence these tests, 24 and the only way to obtain conclusive evidence would be to evaluate coagulation factors in isolation. 25 Klipping & Marr 26 demonstrated an increase in the fibrinogen plasma concentration in patients treated with DRSP/20EE in relation to nontreated patients. Previously published studies [5] [6] [7] [8] [9] [10] have demonstrated that the use of oral contraceptives may favor hypercoagulation, increasing the chances of developing venous thrombosis by providing an increase in the coagulant factors and a decrease in anticoagulation and fibrinolysis. 27 Venous thrombosis is a multifactorial disease with an annual incidence around 50 per 100 000 in patients at 25 years of age and 120 per 100 000 in patients by age 50, and its major complication, the pulmonary embolism, cause death in 1% to 2% of patients. 28 Numerous reports have indicated that the use of oral contraceptives increases the thrombotic risk 2-to 6-fold. 9, 10 This increased risk is associated with the dose of estrogen and the type of progestogen. The second-generation progestins have been shown to be safer than the new progestins and this fact has generated extensive discussions. A large Danish national cohort study analyzed that among 3.3 million of women, 4213 venous thrombotic events were found, among which 2045 events were observed in current users of COCs. 9 The Food and Drug Administration issued addition of information about the risk of thrombosis during the use of contraceptive containing DRSP on the labels, and very recently, a French medicines agency has suspended marketing authorization for pills containing cyproterone acetate combined with 35-mg ethinylestradiol (EE). 29 In our study, users of DRSP/20EE had more hemostatic alterations than the users of DRSP/30EE. These results disagree with the studies that show that the estrogen is the responsible by cause alterations that favor the occurrence of thrombotic events, [5] [6] [7] [8] [9] [10] since DRSP/20EE caused more hypercoagulant alterations. Studies 10, 30 demonstrated that the decrease in the dose of EE (estrogen) from 50 mg to 30 to 20 mg has caused a decrease in the risk of developing thrombosis. Nevertheless, there is no evidence that the risk of thrombosis has decreased due to the changes done in the concentration of estrogen (30-20 mg) . In this comparison, it was possible to observe that the hypercoagulant effect of the contraceptive is not strictly dependent on the dose of estrogen. 31 It is important to note that the women who used the contraceptive containing DRSP/20EE were the ones that showed an increase in the levels of D-dimers, which are fibrin degradation products, and therefore are dependent on fibrin generation and fibrinolysis, becoming When we evaluate the effects of different progestogens (DRSP/30EE vs LNG/30EE), both contraceptives caused the same number of hemostatic alterations. So, we can suggest that this comparison showed inconclusive results, since it was expected that the second-generation progestogen (levonorgestrel) had higher antiestrogenic activity, [14] [15] [16] causing less alterations in the hemostasis. Perhaps the generation of these inconclusive results can be related to the different characteristics observed in each group, for example, BMI, age, and practice of physical exercises.
In this study, we concluded that the contraceptive containing the lowest dose of estrogen DRSP/20EE caused changes in procoagulant, anticoagulant, and fibrinolytic factors, confirming the fact that the hemostatic changes caused by the contraceptives do not depend strictly on the dose of estrogen, being highly related to the anti-estrogenic activity of the progestin. In this case, the progestin drospirenone was found to have lower efficacy to counterbalance the prothrombotic effect provided by the estrogen present in the formulation. These findings can contribute to leave people aware of the risk related to the use of contraceptive containing DRSP.
Some limitations were found in this study, for example, it was difficult to find participants that use the contraceptives containing DRSP/20EE and LNG/30EE because in Brazil, the contraceptive containing DRSP/20EE has a very high cost and is a new drug in comparison to the other available drugs, and the contraceptive containing LNG/30EE is usually used by women over 30 years of age. Furthermore, it was difficult to find women with a profile within the inclusion criteria and in a predetermined period of menstrual cycle to collect blood samples. For these reasons, we have a small sample size what conducted us to consider this work a preliminary study.
